Keyphrases
Randomized Trial
100%
Docetaxel
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Cisplatin
55%
Carboplatin
33%
Vinorelbine
22%
First-line Chemotherapy
22%
Non-small Cell Lung Cancer (NSCLC)
11%
Doublet
11%
Neutropenia
11%
Treatment Options
11%
Metastatic Non-small Cell Lung Cancer
11%
Targeted Agents
11%
Prognostic Factors
11%
Cytotoxic Chemotherapy
11%
Hematotoxicity
11%
Treatment Paradigms
11%
Novel Treatments
11%
Lung Cancer Treatment
11%
Chemotherapy Combinations
11%
Overall Survival of Patients
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Docetaxel
100%
Cisplatin
55%
Carboplatin
33%
Vinorelbine
22%
First-Line Chemotherapy
22%
Overall Survival
11%
Neutropenia
11%
Cytotoxic Chemotherapy
11%